Congratulations, by WMHBThis is an incredibly spot on...

Congratulations, by WMHB

This is an incredibly spot on appointment by Leslie Chong and Imugene. The recruitment of Dr Weitzman can leave no doubt in anyone’s mind in which direction Imugene (IMU - ASX) are heading. Straight onto the path seeking an FDA IND for coverage of all solid tumours via the fast track registrational route. And guess what? Now they have the candidate to oversee, supervise and expedite the transaction. Just so good!

The points I like the most with respect to this appointment are as follows:

Dr Weitzman brings to Imugene over two decades of global experience in the biopharmaceutical industry, with expertise in the therapeutic areas of solid-tumour malignancies. He has an extensive record in creating and executing clinical development plans, directing Phase I - III clinical trials, and preparing US and EU regulatory submissions, including three Investigational New Drug (IND) submissions.

For those understandably bemoaning the beleagured state of the IMU share price understand this, the price is being played with like a pawn, or a toy. Sold down five points and then traded back up five, simply because it can be. These trades have absolutely nothing to do with the stocks underlying fundamentals. Watch closely from here on in toward the end of 2023 how quickly momentum can change, utilising Professor Fong’s speeches and Dr Weitzman's appointment as a guide, if not a barometer, for the temperature, as things start to heat up. It would appear a registrational trial for Vaxinia is on the cards now, and if so that is going to lead to a seismic shift in the prevailing share price. Registering a product with the FDA to treat multiple solid tumours safely represents a cataclysmic change to the status quo in healthcare as we know it. With Dr. Weitzman firmly aboard on the IMU ship it would appear we have the finish line in sight.

DYOR Seek investment advice as and when required Opinions only

P.s It goes without saying our new employee had a stint with Genentech